Silence Therapeutics PLC

Silence Therapeutics plc has successfully priced an upsized underwritten public offering of American Depositary Shares, raising approximately $175 million to advance its siRNA therapies.

Silence Therapeutics plc reported positive topline results from the Phase 2 SANRECO trial of divesiran for polycythemia vera, meeting primary and secondary endpoints and supporting advancement to Phase 3.

Silence Therapeutics plc announced its second quarter 2026 financial and business results, highlighting progress in its Divesiran and SLN312 programs and a reduced net loss.

Silence Therapeutics plc has amended its previous Form 8-K filing to provide further details on the separation agreement with former executive Craig Tooman, including updated compensation and benefits.

Silence Therapeutics plc successfully passed all nine resolutions at its 2026 Annual General Meeting held on June 16, 2026.

Silence Therapeutics presented follow-up data from its Phase 1 SANRECO study of divesiran for polycythemia vera, highlighting durable efficacy and quality-of-life improvements.

Silence Therapeutics plc filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and outlining the need for future capital raises.

Silence Therapeutics plc reported a net loss of $14.96 million for Q1 2026, with a significant decrease in R&D costs and a cash runway extending into 2028.

Silence Therapeutics plc reported increased net losses and decreased revenue for Q3 2025, while advancing its Divesiran and Zerlasiran clinical programs and navigating collaboration changes.

Silence Therapeutics plc reported a significant increase in net loss and a sharp decline in revenue for Q2 2025, while advancing key clinical programs and pausing another.

Silence Therapeutics reports a net loss of $28.53 million for Q1 2025, with a focus on advancing clinical trials and seeking partnerships.

Silence Therapeutics reported a significant net loss of $88.6 million for 2025, alongside AstraZeneca's decision to discontinue further development of SLN312 beyond Phase 1.

Silence Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Silence Therapeutics reports its full year 2024 results, showcasing advancements in its clinical programs and preparations for Phase 3 trials.

Richard Ian Griffiths, a 10% owner of Silence Therapeutics plc, reported multiple transactions in common stock on August 10, 2026.

Richard Ian Griffiths, a director at Silence Therapeutics plc, reported the sale of American Depositary Shares (ADS) and ordinary shares across multiple transactions in late June and early July 2026.

Silence Therapeutics director Richard Ian Griffiths reported internal transfers of American Depositary Shares, maintaining his overall beneficial ownership.

Silence Therapeutics plc Director James Ede-Golightly was granted 90,000 share options with an exercise price of $2.05, vesting over one year.

Silence Therapeutics plc Director Timothy McInerney acquired 90,000 share options with an exercise price of $2.05, vesting over one year.

Silence Therapeutics plc's EVP and Chief R&D Officer, Steven J. Romano, was granted 300,000 employee share options with an exercise price of $2.05.

Silence Therapeutics announces its 2025 Annual General Meeting (AGM) to be held on June 26, 2025, featuring resolutions on director re-appointments, executive compensation, auditor ratification, and adoption of new articles of association.

Richard Griffiths, a director and significant shareholder of Silence Therapeutics Plc, has sold approximately $87.7 million worth of American Depositary Shares (ADSs) in open market transactions.

Richard Griffiths and associated entities report a significant sale of Silence Therapeutics Plc ADSs, reducing their beneficial ownership.

Richard Griffiths, a significant shareholder, has increased his beneficial ownership in Silence Therapeutics Plc to 24.4% through recent open market purchases totaling $2.7 million.

Richard Ian Griffiths, a significant shareholder in Silence Therapeutics Plc, increased his beneficial ownership to 23.2% through open market purchases totaling $2.4 million, despite a concurrent dilution from the Issuer's increased share capital.

Richard Ian Griffiths, a director and controlling shareholder of Silence Therapeutics Plc, has significantly increased his beneficial ownership in the company through recent open market purchases totaling $1.6 million.

Richard Ian Griffiths, through various controlled entities, has increased his beneficial ownership in Silence Therapeutics Plc to 20.7% of outstanding ordinary shares following recent open market purchases totaling $3.0 million.

A filing reveals that Invus Public Equities, L.P. and affiliated entities now collectively beneficially own 7.0% of Silence Therapeutics plc's ordinary shares.

Lombard Odier Asset Management (USA) Corp reported a 4.2% beneficial ownership stake in Silence Therapeutics plc as of December 31, 2025.

Redmile Group, LLC and its principal, Jeremy C. Green, have reported a combined beneficial ownership of 4.7% of Silence Therapeutics plc's Ordinary Shares, held through private investment vehicles.

Investment firm Redmile Group, LLC and its principal Jeremy C. Green have disclosed a beneficial ownership of 5.1% in Silence Therapeutics plc, holding over 7.1 million ordinary shares as of December 31, 2024.

Lombard Odier Asset Management (USA) Corp has filed an amended Schedule 13G, reporting a beneficial ownership of 7.6% in Silence Therapeutics plc as of December 31, 2024.